While the decline in Revlimid revenues will continue to weigh on near-term earnings, Dr. Reddy's core business remains healthy. Strong growth in India and Emerging Markets, along with stable contributions from the NRT portfolio, is helping offset pricing pressure in the U.S. generics business.